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background: Acute myocardial infarction (AMI) is now a major cause of emergency medical care, hospitalization and mortality in China. However 
there are limited information on how clinical characteristics, care quality and outcome vary among Chinese patients and hospitals. We launched the 
China AMI (CAMI) registry, as a national registry to obtain real-world information on AMI epidemiology, treatment, outcome and cost.
methods: The CAMI registry was designed as a prospective, multicenter, observational registry with an integrated research and education platform 
for AMI care. Eligible patients must be admitted within 7 days of acute ischemic symptoms with a primary diagnosis of AMI [ST elevation myocardial 
infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI)]. Clinical data, laboratory and imaging results, treatments, outcomes and cost 
are to be collected. Follow-up visits are planned through 2 years.
results: The registry was launched in January 2013. At the time of this abstract submission, 102 different-level hospitals (including province level, 
district level, and county level representing typical Chinese governmental models) from 27 provinces and 4 large cities (municipalities directly under 
central government) throughout mainland of China are participating in the registry. Through September 2013, 8,185 patients with AMI (71.4% STEMI 
patients, 25.1% NSTEMI patients and 3.5% patients uncertain) have been enrolled. 74.9% of patients were male. The median age was 63 years (22-
99 years). 52% of patients had hypertension and 20% had diabetes. 46.3% of patients were current smokers. 95.2% of patients received aspirin, 
94.5% received clopidogrel and 97.2% received a statin. The in-hospital mortality rate was 5.3% for STEMI and 4.2% for NSTEMI. At the Scientific 
Sessions the authors will present further data on early results.
Conclusions: The CAMI registry represents a novel unified, national AMI registry-research-education platform for surveillance, multicenter clinical 
research, and quality improvement for AMI care in China, a geographically large and economically diverse country that is the most populous in the 
world. These represent the first results from CAMI.
